Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Aeterna Zentaris and EMD Serono have finalized a promotional services agreement that will allow Aeterna Zentaris to promote Saizen [somatropin (rDNA origin) for injection] to designated medical professionals in specified territories in the US.
Subscribe to our email newsletter
Saizen is a recombinant human Growth Hormone (r-hGH) registered in the US to treat growth hormone deficiency (GHD) in children and adults.
As part of the deal, Aeterna will detail Saizen to designated medical professionals, representing an important incremental field promotion activity in support of the product.
Aeterna will receive payment based on new, eligible patient starts on Saizen above an agreed-upon baseline.
Aeterna Zentaris senior vice-president and chief commercial officer Jude Dinges said: "In collaboration with Ascend Therapeutics, our combined 53 sales representatives are eager and poised to begin detailing Saizen.
"We recognize the value of direct promotion in this category and we look forward to achieving increased market share and growth for Saizen by significantly increasing the share-of-voice and impact in support of the product."
The company has subcontracted with Ascend Therapeutics US with whom it previously established a co-promotion agreement that is currently underway, to detail Saizen in territories not covered by Aeterna Zentaris.